Anti-interleukin-6 therapy in rheumatoid arthritis

Download in PDF

Currently, biologic agents, including tocilizumab (monoclonal antibodies to interleukin-6 receptors), are widely used for disease-modifying treatment in patients with rheumatoid arthritis, particularly with refractory forms not responding to metothrexate and other standard treatments.The review summarizes the results of long-term therapy with tocilizumab, its immunogenicity and the risk of cardiovascular outcomes and infections.

Key words

Rheumatoid arthritis, interleukin-6, tocilizumab, long-term therapy, safety.